|
Kelly CRISPR & Gene Editing Technology ETF | XDNA | ETFMG Travel Tech ETF | AWAY | Global X Guru Index ETF | GURU | Capital Link Global Fintech Leaders ETF | KOIN | Global X Health & Wellness ETF | BFIT | Gotham Neutral Fund Institutional Class | GONIX | SPAC and New Issue ETF | SPCX | Forian Inc | FORA | Kelly Residential & Apartment Real Estate ETF | RESI | AXS Cannabis ETF | THCX |
Gross Expense Ratio*
0.78%
SEC 30 Day Yield (as of 05/31/23 )
--
Ann. Dividend/Yield
$0.0093/0.10%
Ex-Dividend Date
12/22/2022
Fund Inception
01/12/2022
|
 Loading...
The chart is currently unavailable.
|
The investment seeks to track the total return performance of the Strategic CRISPR & Gene Editing Technology Index.The adviser employs a “passive management” investment approach designed to track the total return performance of the index. The index is a rules-based index that consists of the stocks or corresponding depositary receipts of companies engaged in the creation, development, production, operation, provision, distribution, ownership, servicing, licensing, leasing or franchising of at least one of the DNA Modification Technology Business. The fund invests at least 80% of its net assets in DNA Modification Technology Companies. It is non-diversified.
|
Market Return % (as of 05/31/2023) |
NAV Return % (as of 05/31/2023) |
Market Return % (as of 03/31/2023) |
NAV Return % (as of 03/31/2023) |
1-Month |
+1.15% |
+0.94% |
-12.95% |
-13.13% |
3-Month |
-10.97% |
-11.81% |
-10.54% |
-10.46% |
6-Month |
-21.93% |
-21.51% |
-24.06% |
-23.83% |
Year-to-date |
-8.51% |
-9.11% |
-10.54% |
-10.46% |
1-Year |
-6.83% |
-7.11% |
-29.13% |
-28.35% |
3-Year |
-- |
-- |
-- |
-- |
5-Year |
-- |
-- |
-- |
-- |
10-Year |
-- |
-- |
-- |
-- |
Since Inception |
-29.34% |
-29.70% |
-33.88% |
-33.85% |
Inception Date: January 12, 2022
Performance Details
Total return reflects performance without adjusting for sales charges or the effects of taxation, but is adjusted to reflect all actual ongoing fund expenses and assumes reinvestment of dividends and capital gains. If adjusted, sales charges would reduce the performance quoted. Performance data quoted represents past performance, is no guarantee of future results, and may not provide an adequate basis for evaluating the performance potential of the product over varying market conditions or economic cycles. Current performance may be higher or lower than the performance data quotes. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost.
|
Market Return % (as of 05/31/2023) |
NAV Return % (as of 05/31/2023) |
Market Return % (as of 03/31/2023) |
NAV Return % (as of 03/31/2023) |
1-Year |
-6.83% |
-7.11% |
-29.13% |
-28.35% |
5-Year |
-- |
-- |
-- |
-- |
10-Year |
-- |
-- |
-- |
-- |
Since Inception |
-29.34% |
-29.70% |
-33.88% |
-33.85% |
Inception Date: January 12, 2022
Cyclical |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
Defensive |
100.00% |
0.00% |
100.00% |
0.00% |
Sensitive |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
Portfolio Details
|
* represents an International company or one without a recognizable symbol.
Portfolio Details
|
|
|